Seeking Alpha

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

- Current Clinical Evidence and Physician Experience Support SCS Injection as a Safe and Effective Method for Delivering Retinal and Choroidal Therapeutics - The publication, entitled, “Suprachoroidal ...
Nasdaq

Clearside Biomedical Highlights CLS-AX Progress and Suprachoroidal Drug Delivery Innovations at ARVO 2025 Meeting

Clearside Biomedical presented data on CLS-AX and its SCS delivery platform at the ARVO 2025 Meeting, highlighting treatment advancements for retinal diseases. Clearside Biomedical, Inc. has announced ...
Nasdaq

Clearside Biomedical, Inc. Explores Strategic Alternatives to Advance SCS Delivery Platform and CLS-AX Development for Retinal Diseases

Clearside Biomedical, Inc. announced its exploration of strategic alternatives to advance its suprachoroidal drug delivery platform and maximize stockholder value. The company, which specializes in ...
Business Insider

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery - - Current Clinical Evidence and Physician Experience Support ...